References
Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975;1:1010–3.
Cohen A, Doyle D, Martin DW, Ammann AJ. Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. N Engl J Med 1976;295:1449–54.
Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s). Proc Natl Acad Sci USA 1977;74:5677–81.
Sircar JC, Gilbertsen RB. Purine nucleoside phosphorylase (PNP) inhibitors: potentially selective immunosuppressive agents. Drugs Future 1988;13:653–68.
Sugiura M, Kato K, Adachi T, Ito Y, Hirano K, Sawaki S. An enzymic method for the determination of inorganic phosphate in serum. Chem Pharm Bull 1981;29:1451–5.
Stoeckler JD, Parks RE, Jr. Purine nucleoside phosphorylase. Measurement of activity and use of inhibitors. In: D.M. Paton, editor. Methods in Pharmacology. New York: Plenum, 1985: 147–162.
Gilbertsen RB, Dong MK. Effects of 8-aminoguanosine, an inhibitor of purine nucleoside phosphorylase, on plasma nucleosides in Wistar rats. Ann NY Acad Sci 1985;451:313–4.
Krstulovic AM, Brown PR, Rosie DM. Identification of nucleosides and bases in serum and plasma samples by reverse-phase high performance liquid chromatography. Anal Chem 1977;49:2237–41.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kimble, E., Hadala, J., Ludewig, R. et al. The biochemical and pharmacological activity of 9-benzyl-9-deazaguanine, a potent purine nucleoside phosphorylase (PNP) inhibitor. Inflamm Res 44 (Suppl 2), S181–S182 (1995). https://doi.org/10.1007/BF01778321
Issue Date:
DOI: https://doi.org/10.1007/BF01778321